Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

US Patent 12077584 · Granted Sep 3, 2024

Estimated economic value: $227,995,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Glypican-3-binding fibronectin based scaffold molecules2025
Activatable anti-CTLA-4 antibodies and uses thereof2025
Antibodies binding to ILT42025
Antibodies binding to ILT42025
Antibodies binding to ILT42025
Methods of treatment or prevention of immune responses and inflammatory diseases2025
Antagonistic CD40 monoclonal antibodies and uses thereof2025
Tumor necrosis factor-like ligand 1A specific antibodies and compositions and us2025
Anti-Dectin-2 antibodies and methods of using2025
Antibodies against TIM3 and uses thereof2025
Antibodies against TIM3 and uses thereof2025
Antibodies against TIM3 and uses thereof2025